<DOC>
	<DOCNO>NCT00719043</DOCNO>
	<brief_summary>The purpose study determine whether GSK 's avian flu vaccine GSK 1557484A immunogenic safe give adult age &gt; =18 year . This Protocol Posting update follow Amendments 1-3 Protocol , Dec 2009 . The impacted section study design outcome measure .</brief_summary>
	<brief_title>Immunogenicity &amp; Safety GSK 's Avian Flu Vaccine 1557484A Given Adults Aged ≥18 Years</brief_title>
	<detailed_description>All subject receive 3 dos study vaccine , include 2 dos active vaccine 1 dose placebo . All subject attend formal study center visit safety immunogenicity assessment Days 0 , 10 , 42 , 182 , 192 , 224 , 549 , 559 , 591 , 729 . A telephone contact ass safety make Day 364 Day 909 .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female 18 year age old time first vaccination . Written inform consent obtain subject . Stable health status define absence health event satisfy definition serious adverse event , change ongoing drug therapy due therapeutic failure symptom drug toxicity , within 1 month prior enrollment . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device . Comprehension study requirement , express availability require study period , ability attend schedule visit . Subjects investigator believe comply requirement protocol Presence evidence substance abuse neurological psychiatric diagnosis , even clinically stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Diagnosed cancer , treatment cancer , within 3 year . Persons history cancer diseasefree without treatment 3 year eligible . Persons history histologicallyconfirmed basal cell carcinoma skin successfully treat local excision except may enroll within 3 year diagnosis , histologic type skin cancer require 3 year untreated diseasefree window . Women diseasefree 3 year treatment breast cancer receive longterm prophylactic tamoxifen except may enroll . Presence oral temperature ≥ 37.8ºC , acute symptom great `` mild '' severity schedule date first vaccination . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Receipt systemic glucocorticoid ( prednisone &gt; = 10 mg/day 14 consecutive day ) within 1 month prior study enrollment , cytotoxic immunosuppressive drug within 6 month study enrollment . Any significant disorder coagulation treatment Coumadin derivatives heparin . Administration vaccine within 30 day first study vaccine dose . Previous administration H5N1 vaccine . Use investigational nonregistered product ( drug vaccine ) plan participation another investigational study within 30 day prior study enrollment , 18 month follow first test article dose . Use investigational nonregistered product immunosuppressive property exclusionary time trial . Receipt immunoglobulins and/or blood product within 6 month study enrollment plan administration product study period . Any known suspected allergy constituent influenza vaccine ( include egg proteins mercurial preservative ) ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin ( βhCG ) test result prior vaccination . Lactating nursing . Women child bear potential lack history reliable contraceptive practice . The provision history NOT replace requirement perform , obtain negative result pregnancy urine test prior treatment . Known receipt analgesic antipyretic medication specific intent prophylaxis vaccine reactogenicity day first treatment . Subjects stable chronic regimen potentially analgesic antipyretic medication preexist diagnosis require discontinue ( would represent evaluation combine vaccine reactogenicity AND treatment withdrawal intent protocol ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>H5N1</keyword>
	<keyword>Avian</keyword>
	<keyword>Vaccines</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Pandemic</keyword>
	<keyword>Human</keyword>
</DOC>